Korea-Japan Alliance Brings Together Japan’s Regenerative Medicine Expertise with Korea’s Cell Manufacturing and Clinical Infrastructure<

Machine-translated from Korean:

The Korea Daily

9.11.26

Japan’s KOHJIN BIO Signs Strategic Three-Way MOU with GenCelix and DKMG

https://www.koreadaily.com/article/20260911001628287

Note:

• Japan's Kohjin market cap is $28 million.

• The 2 Korean companies are privately held.